BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
MWN-AI** Summary
BioVie Inc. (NASDAQ: BIVI), a clinical-stage biopharmaceutical company, recently announced that its abstract detailing the SUNRISE-PD study of bezisterim (NE3107) has been accepted for presentation at the upcoming AD/PD 2026 Advances in Science & Therapy conference. Scheduled for March 17-21, 2026, in Copenhagen, Denmark, this annual event focuses on advancements in the treatment and research of Alzheimer’s and Parkinson’s diseases.
The accepted abstract, authored by a team from BioVie and partner institutions, provides insights into the demographics and baseline characteristics of patients enrolled in the SUNRISE-PD study. This trial evaluates the efficacy of bezisterim in early Parkinson's disease patients who have not previously been treated with carbidopa/levodopa. Given the promising results of earlier studies demonstrating improved motor control with fewer side effects when combining bezisterim with levodopa, the upcoming topline results from this study are highly anticipated in mid-2026.
Bezisterim is designed to cross the blood-brain barrier, tackling neuroinflammation and improving insulin sensitivity while minimizing the risk of drug interactions. Its promising applications stretch beyond Parkinson’s disease, as it is also being evaluated for efficacy in treating Long COVID symptoms and has shown potential in Alzheimer’s disease through prior Phase 2 and Phase 3 trials, which indicated cognitive improvements.
BioVie is not only advancing bezisterim for neurodegenerative conditions but is also progressing its treatment BIV201 for advanced liver disease, which has received FDA Orphan Drug and Fast Track designations. As the landscape of treatments for neurological disorders evolves, BioVie’s ongoing studies and upcoming results could significantly impact therapeutic strategies for millions affected globally. For further details, visit BioVie’s official website.
MWN-AI** Analysis
BioVie Inc. (NASDAQ: BIVI) has recently gained significant traction with the announcement of its abstract presentation at the upcoming AD/PD 2026 conference, primarily focusing on bezisterim (NE3107) for Parkinson's Disease. This announcement comes in conjunction with positive insights from the SUNRISE-PD study, which may catalyze investor interest and market movement.
First, it's important to note the clinical potential of bezisterim, which exhibits promising results in prior trials by improving motor control in Parkinson's Disease patients with minimal side effects. This therapeutic trend is critical, as Parkinson's represents a growing health challenge with limited effective treatments. As topline results from the ongoing SUNRISE-PD study are anticipated in mid-2026, investors should prepare for potential volatility around this release, as positive outcomes could significantly enhance the company's valuation and stock price.
Moreover, BioVie’s multi-pronged approach in treating related conditions like Long COVID and Alzheimer’s Disease broadens its market appeal. The data presented at the AD/PD conference could not only spotlight bezisterim's applicability in Parkinson's but also bolster the company’s profile for other neurodegenerative diseases, creating investor enthusiasm.
However, it is essential to temper excitement with caution. Market dynamics can be unpredictable, especially in the biotech sector where clinical data can diverge dramatically from initial expectations. Potential investors should consider component factors such as overall market conditions, and therapeutic competition, and remember the risks inherent in clinical-stage companies, including the possibility of trial failures.
Overall, BioVie's approaching data readouts represent a critical pivot point that could lead to substantial returns for investors willing to navigate the associated risks for potential leverage in a burgeoning neurological therapeutics market. Continuous monitoring of upcoming trial data and investor sentiment post-presentation will be crucial for strategic positioning.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming AD/PD 2026 Advances in Science & Therapy annual meeting, to be held March 17-21, 2026 in Copenhagen, Denmark.
The abstract, titled Demographics and Baseline Characteristics of Participants in a Study of Bezisterim (NE3107) in Early Parkinson’s Disease (SUNRISE-PD) (J. Palumbo1, C Ahlem1, C.L. Reading1, S. O’Quinn2, J. Zhang3, M. Stacy4), summarizes the initial data on patients enrolled in the SUNRISE-PD study, and will be presented as a poster. Topline results from the SUNRISE-PD study are expected in mid?2026.
The AD/PD™ Alzheimer’s Disease and Parkinson’s Disease Conference will present all the latest breakthroughs in treatment, translational R&D, early diagnosis, drug development, and clinical trials in Alzheimer’s, Parkinson’s, and other related neurological disorders.
Affiliations: 1BioVie, Inc, 2Perissos, Inc., 3Princeton Pharmatech, 4Medical University of South Carolina
About Bezisterim
Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NF?B, TNF-?), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease.
In Parkinson’s disease, BioVie has already completed a Phase 2 study that showed patients with moderate-to severe Parkinson’s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid?2026.
For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NF?B activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026.
In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s.
About BioVie Inc.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.
In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.
| For Investor Relations Inquiries: | For Media Inquiries: |
| Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC chuck@lifesciadvisors.com | Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com |
FAQ**
How does BioVie Inc. (BIVI) plan to leverage the topline results from the SUNRISE-PD study to enhance investor confidence and interest in its pipeline, particularly in the context of Parkinson's disease treatment?
With the upcoming presentation of the SUNRISE-PD study at the AD/PD 20conference, how does BioVie Inc. (BIVI) anticipate this exposure will impact its stock performance and market perception?
What strategies does BioVie Inc. (BIVI) have in place to address potential risks associated with drug development, especially as it relates to the outcomes of the current trials for bezisterim (NE3107)?
Considering BioVie Inc. (BIVI) is pursuing multiple indications for bezisterim, how does the company prioritize its resources and strategic focus across Parkinson's disease, Long COVID, and Alzheimer's disease?
**MWN-AI FAQ is based on asking OpenAI questions about BioVie Inc. (NASDAQ: BIVI).
NASDAQ: BIVI
BIVI Trading
4.47% G/L:
$1.3999 Last:
22,680 Volume:
$1.39 Open:
